entertainment -WSS

entertainment

author：entertainment 2025-09-30 09:03:28 - browse：6

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： There's an unseen cost to disruptive road

knowledge

WSS

Addressing health care workers' trauma can help fight burnout

There's an unseen cost to disruptive road

Bird flu surveillance in wastewater gets boost from consortium

Study finds gene variants tied to breast cancer risk in Black women

FDA endorses new sterilization method for medical devices

What causes osteoarthritis? Researchers study link to brain protein

knowledge

entertainment

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Fentanyl is making it harder to start addiction treatment

Medical leaders decry Supreme Court decision on affirmative action

TikTok, Instagram influencers need more rules for drug ads

How to save PrEP access — and even expand it

As a primary care physician, here's how I hope to partner with AI

New air purifier tech could be key to improving indoor air quality

As a primary care physician, here's how I hope to partner with AI

How one medical school became remarkably diverse

Listen: A conversation with researcher Kevin Esvelt on biosecurity

hotspot

Pumping milk in bathrooms at health conferences is common

Pumping milk in bathrooms at health conferences is common

Liver decline slowed by off

Cue Health, Covid

Liver decline slowed by off

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

explore

explore

knowledge

entertainment